ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 585,95
-0,24%
Dow Jones
42 208,22
0,00%
DAX
18 948,45
-0,21%
Brent Oil
73,58
-1,31%
Bitcoin
63 550,80
-1,12%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Novartis AG (NVS)

  7. Novartis AG (NVS) Actualités

NVS

Novartis (NVS)

Novartis AG
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:NVS
DateHeureSourceTitreSymboleSociété
16/09/202414h44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:NVSNovartis AG
16/09/202414h12Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:NVSNovartis AG
16/09/202412h03IH Market NewsIntel Secures $3.5 Billion Subsidy, Stellantis Backs EU Emissions Targets, BP and Apollo Reach $1 Billion DealNYSE:NVSNovartis AG
11/09/202400h53AllPennyStocks.comJunior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving LivesNYSE:NVSNovartis AG
05/09/202414h00GlobeNewswire Inc.Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14NYSE:NVSNovartis AG
28/08/202418h16Business WireLindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitargetNYSE:NVSNovartis AG
28/08/202418h07Business WireLindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiplesNYSE:NVSNovartis AG
28/08/202418h06Business WireLindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle abNYSE:NVSNovartis AG
28/08/202412h58Business WireLindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery InnovationNYSE:NVSNovartis AG
26/08/202414h58IH Market NewsIBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without AstronautsNYSE:NVSNovartis AG
15/08/202422h30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NYSE:NVSNovartis AG
13/08/202422h31Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
12/08/202421h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:NVSNovartis AG
08/08/202401h38PR Newswire (US)Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)NYSE:NVSNovartis AG
06/08/202411h44IH Market NewsGoogle Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business NewsNYSE:NVSNovartis AG
30/07/202413h00GlobeNewswire Inc.Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNYSE:NVSNovartis AG
18/07/202412h09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:NVSNovartis AG
18/07/202411h53IH Market NewsTSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit SurgeNYSE:NVSNovartis AG
17/06/202422h30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:NVSNovartis AG
25/05/202412h15PR Newswire (US)Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolioNYSE:NVSNovartis AG
25/05/202412h00PR Newswire (US)Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placeboNYSE:NVSNovartis AG
07/05/202413h00GlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNYSE:NVSNovartis AG
23/04/202413h25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:NVSNovartis AG
15/04/202420h00PR Newswire (US)New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)NYSE:NVSNovartis AG
11/04/202413h00GlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNYSE:NVSNovartis AG
10/04/202413h13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:NVSNovartis AG
06/04/202422h16PR Newswire (US)New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world settingNYSE:NVSNovartis AG
15/02/202422h15Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNYSE:NVSNovartis AG
06/02/202422h52Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNYSE:NVSNovartis AG
06/02/202412h14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNYSE:NVSNovartis AG
 Showing the most relevant articles for your search:NYSE:NVS

Dernières Valeurs Consultées

BTRX
1PECOUSDT
1peco coin
ASX
UNT
Unith
TG
BU9
Resouro Gold
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés